Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate UpdateBusiness Wire • 05/13/25
Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of DirectorsGlobeNewsWire • 05/08/25
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 04/29/25
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data ReleaseSeeking Alpha • 04/25/25
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal DementiaBusiness Wire • 04/24/25
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?Zacks Investment Research • 04/23/25
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)Business Wire • 04/21/25
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025Business Wire • 04/01/25
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a BetZacks Investment Research • 03/27/25
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome ProgramBusiness Wire • 03/26/25
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial ResultsBusiness Wire • 03/18/25
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and CombinationsBusiness Wire • 02/25/25
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly DosingBenzinga • 02/06/25
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical DevelopmentBusiness Wire • 02/06/25
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/04/25
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory DiseasesBusiness Wire • 01/21/25
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)Business Wire • 12/18/24
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx ConferenceBusiness Wire • 11/25/24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial ResultsBusiness Wire • 11/06/24
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive OfficerBusiness Wire • 11/01/24